尼曼匹克病C型诊疗新进展

任守臣; 高宝勤

doi:10.7499/j.issn.1008-8830.2015.05.025

PDF(1510 KB)

HTML

中国当代儿科杂志 ›› 2015, Vol. 17 ›› Issue (5) : 533-538. DOI: 10.7499/j.issn.1008-8830.2015.05.025

综述

尼曼匹克病C型诊疗新进展

任守臣, 高宝勤

作者信息 +

Research advances in diagnosis and therapy of Niemann-Pick disease type C

REN Shou-Chen, GAO Bao-Qin

Author information +

文章历史 +

摘要

尼曼匹克病C型(NPC)是一种常染色体隐性遗传的溶酶体脂质贮积病, 主要累及内脏器官和神经系统, 自婴幼儿至成人均可发病, 儿童期多见。新生儿期持续存在的胆汁淤积性黄疸、脾脏肿大、猝倒发作和垂直性核上性眼肌麻痹为该病的特征性表现, 因发病年龄不同, 首发的神经系统症状不一致, 临床有明显的异质性。NPC基因缺陷导致游离胆固醇转运障碍, 在细胞内大量沉积是疾病的始发因素, 细胞的自噬功能障碍、钙稳态失平衡、氧化应激等均参与疾病的病理生理过程。通过皮肤成纤维细胞培养发现异常沉积的游离胆固醇或行基因检查发现NPC的致病性突变可确诊该病。美格鲁特是唯一被批准上市的特效药物, 早期应用可以改善神经系统症状和延缓疾病的进展。

Abstract

Niemann-Pick disease type C (NPC) is an autosomal recessive lysosomal lipid storage disease associated with impaired intracellular cholesterol trafficking. A wide spectrum of clinical phenotype has been described, with a possible onset at all ages of life from the neonatal period to adulthood, more often in childhood. Typically, hepatosplenomegaly, dystaxia, dysphagia, dysarthria and dementia are presented in NPC patients. Neurologic symptoms vary according to the onset age, but prolonged neonatal cholestasis, splenomegaly, cataplexy and vertical supranuclear gaze palsy are more specific signs to the diagnosis of the disease. Impaired cholesterol trafficking and unesterified cholesterol accumulation in the late endosomes and lysosomals, as a results of mutations in NPC1 or NPC2 genes, are initial for the disease, and defective cellular autophagy, defective lysosomal calcium homeostasis and oxidative stress may all play roles in the physiological processes. The definite diagnosis requires demonstration of unesterified cholesterol accumulated in fibroblasts cultured from skin biopsies or of pathogenic mutation of NPC1/NPC2 genes. Miglustat, the only available treatment approved to date, can alleviate neurological symptoms and slow disease progression when administered earlier.

导出引用

任守臣, 高宝勤. 尼曼匹克病C型诊疗新进展[J]. 中国当代儿科杂志. 2015, 17(5): 533-538 https://doi.org/10.7499/j.issn.1008-8830.2015.05.025

REN Shou-Chen, GAO Bao-Qin. Research advances in diagnosis and therapy of Niemann-Pick disease type C[J]. Chinese Journal of Contemporary Pediatrics. 2015, 17(5): 533-538 https://doi.org/10.7499/j.issn.1008-8830.2015.05.025

参考文献

[1] Vanier MT. Niemann-Pick disease type C[J]. J Orphanet J Rare Dis, 2010, 5: 16.
[2] Patterson MC, Hendriksz CJ, Walterfang M, et al. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update[J]. Mol Genet Metab, 2012, 106(3): 330-344.
[3] Mengel E, Klunemann HH, Lourenco CM, et al. Niemann-Pick disease type C symptomatology: an expert-based clinical description[J]. Orphanet J Rare Dis, 2013, 8: 166.
[4] Wijburg FA, Sedel F, Pineda M, et al. Development of a suspicion index to aid diagnosis of Niemann-Pick disease type C[J]. Neurology, 2012, 78(20): 1560-1567.
[5] Oyama K, Takahashi T, Shoji Y, et al. Niemann-Pick disease type C: cataplexy and hypocretin in cerebrospinal fluid[J]. Tohoku J Exp Med, 2006, 209(3): 263-267.
[6] Greer WL, Riddell DC, Byers DM, et al. Linkage of Niemann-Pick disease type D to the same region of human chromosome 18 as Niemann-Pick disease type C[J]. Am J Hum Genet, 1997, 61(1): 139-142.
[7] Millat G, Marçais C, Tomasetto C, et al. Niemann-Pick C1 disease: correlations between NPC1 mutations, levels of NPC1 protein, and phenotypes emphasize the functional significance of the putative sterol-sensing domain and of the cysteine-rich luminal loop[J]. Am J Hum Genet, 2001, 68(6): 1373-1385.
[8] Storch J, Xu Z. Niemann-Pick C2 (NPC2) and intracellular cholesterol trafficking[J]. Biochim Biophys Acta, 2009, 1791(7): 671-678.
[9] Abi-Mosleh L, Infante RE, Radhakrishnan A, et al. Cyclodextrin overcomes deficient lysosome-to-endoplasmic reticulum transport of cholesterol in Niemann-Pick type C cells[J]. Proc Natl Acad Sci U S A, 2009, 106(46): 19316-19321.
[10] Dixit SS, Jadot M, Sohar I, et al. Loss of Niemann-Pick C1 or C2 protein results in similar biochemical changes suggesting that these proteins function in a common lysosomal pathway[J]. PLoS One, 2011, 6(8): e23677.
[11] Millat G, Marçais C, Tomasetto C, et al. Niemann-Pick C1 disease: correlations between NPC1 mutations, levels of NPC1 protein, and phenotypes emphasize the functional significance of the putative sterol-sensing domain and of the cysteine-rich luminal loop[J]. Am J Hum Genet, 2001, 68(6): 1373-1385.
[12] Vanier MT, Wenger DA, Comly ME, et al. Niemann-Pick disease group C: clinical variability and diagnosis based on defective cholesterol esterification. A collaborative study on 70 patients[J]. Clin Genet, 1988, 33(5): 331-348.
[13] 章瑞南, 邱文娟, 叶军, 等. 尼曼-匹克病C型一家系基因突变分析及产前基因诊断[J]. 中华围产医学杂志, 2013, 16(12): 750-755.
[14] Xiong H, Higaki K, Wei CJ, et al. Genotype/phenotype of 6 Chinese cases with Niemann-Pick disease type C[J]. Gene, 2012, 498(2): 332-335.
[15] Yang CC, Su YN, Chiou PC, et al. Six novel NPC1 mutations in Chinese patients with Niemann-Pick disease type C[J]. Neurol Neurosurg Psychiatry, 2005, 76(4): 592-595.
[16] Millat G, Marçais C, Rafi MA, et al. Niemann-Pick C1 disease: the I1061T substitution is a frequent mutant allele in patients of Western European descent and correlates with a classic juvenile phenotype[J]. Am J Hum Genet, 1999, 65(5): 1321-1329.
[17] Mesmin B, Maxfield FR. Intracellular sterol dynamics[J]. Biochim Biophys Acta, 2009, 1791(7): 636-645.
[18] Rosenbaum AI, Maxfield FR. Niemann-Pick type C disease: molecular mechanisms and potential therapeutic approaches[J]. J Neurochem, 2011, 116(5): 789-795.
[19] Zervas M, Dobrenis K, Walkley SU. Neurons in Niemann-Pick disease type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations[J]. Neuropathol Exp Neurol, 2001, 60(1): 49-64.
[20] te Vruchte D, Lloyd-Evans E, Veldman RJ, et al. Accumulation of glycosphingolipids in Niemann-Pick C disease disrupts endosomal transport[J]. Biol Chem, 2004, 279(25): 26167-26175.
[21] Singh R, Cuervo AM. Lipophagy: connecting autophagy and lipid metabolism[J]. Int J Cell Biol, 2012, 2012: 282041.
[22] Ravikumar B, Sarkar S, Davies JE, et al. Regulation of mammalian autophagy in physiology and pathophysiology[J]. Physiol Rev, 2010, 90(4): 1383-1435.
[23] Mizushima N, Levine B, Cuervo AM, et al. Autophagy fights disease through cellular self-digestion[J]. Nature, 2008, 451(7182): 1069-1075.
[24] Komatsu M. Liver autophagy: physiology and pathology[J]. J Biochem, 2012, 152(1): 5-15.
[25] Sarkar S. Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers[J]. Biochem Soc Trans, 2013, 41(5): 1103-1130.
[26] Peake KB, Vance JE. Normalization of cholesterol homeostasis by 2-hydroxypropyl-β-cyclodextrin in neurons and glia from Niemann-Pick C1 (NPC1)-deficient mice[J]. J Biol Chem, 2012, 287(12): 9290-9298.
[27] Meske V, Erz J, Priesnitz T, et al. The autophagic defect in Niemann-Pick disease type C neurons differs from somatic cells and reduces neuronal viability[J]. J Neurobiol Dis, 2014, 64: 88-97.
[28] Sarkar S, Carroll B, Buganim Y, et al. Impaired autophagy in the lipid-storage disorder Niemann-Pick type C1 disease[J]. Cell Rep, 2013, 5(5): 1302-1315.
[29] Lloyd-Evans E, Morgan AJ, He X, et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium[J]. Nat Med, 2008, 14(11): 1247-1255.
[30] Vázquez MC, Balboa E, Alvarez AR, et al. Oxidative stress: a pathogenic mechanism for Niemann-Pick type C disease[J]. Oxid Med Cell Longev, 2012, 2012: 205713.
[31] Walkley SU, Suzuki K. Consequences of NPC1 and NPC2 loss of function in mammalian neurons[J]. Biochim Biophys Acta, 2004, 1685(1-3): 48-62.
[32] Elrick MJ, Pacheco CD, Yu T, et al. Conditional Niemann-Pick C mice demonstrate cell autonomous Purkinje cell neurodegeneration[J]. Hum Mol Genet, 2010, 19(5): 837-847.
[33] Buard I, Pfrieger FW. Relevance of neuronal and glial NPC1 for synaptic input to cerebellar Purkinje cells[J]. Mol Cell Neurosci, 2014, 61: 65-71.
[34] Sarna JR, Larouche M, Marzban H, et al. Patterned Purkinje cell degeneration in mouse models of Niemann-Pick type C disease[J]. J Comp Neurol, 2003, 456(3): 279-291.
[35] Macauley SL, Sidman RL, Schuchman EH, et al. Neuropathology of the acid sphingomyelinase knockout mouse model of Niemann-Pick A disease including structure-function studies associated with cerebellar Purkinje cell degeneration[J]. Exp Neurol, 2008, 214(2): 181-192.
[36] Yu T, Shakkottai VG, Chung C, et al. Temporal and cell-specific deletion establishes that neuronal Npc1 deficiency is sufficient to mediate neurodegeneration[J]. Hum Mol Genet, 2011, 20(22): 4440-4451.
[37] Lopez ME, Klein AD, Dimbil UJ, et al. Anatomically defined neuron-based rescue of neurodegenerative Niemann-Pick type C disorder[J]. Neurosci, 2011, 31(12): 4367-4378.
[38] Erickson RP. Current controversies in Niemann-Pick C1 disease: steroids or gangliosides; neurons or neurons and glia[J]. Appl Genet, 2013, 54(2): 215-224.
[39] Wraith JE, Sedel F, Pineda M, et al. Niemann-Pick type C Suspicion Index tool: analyses by age and association of manifestations[J]. Inherit Metab Dis, 2014, 37(1): 93-101.
[40] Rodrigues AF, Gray RG, Preece MA, et al. The usefulness of bone marrow aspiration in the diagnosis of Niemann-Pick disease type C in infantile liver disease[J]. Arch Dis Child, 2006, 91(10): 841-844.
[41] Patterson MC, Hendriksz CJ, Walterfang M, et al. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update[J]. Mol Genet Metab, 2012, 106(3): 330-344.
[42] Porter FD, Scherrer DE, Lanier MH, et al. Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease[J]. Sci Transl Med, 2010, 2(56): 56ra81.
[43] Jiang X, Sidhu R, Porter FD, et al. A sensitive and specific LC-MS/MS method for rapid diagnosis of Niemann-Pick C1 disease from human plasma[J]. Lipid Res, 2011, 52(7): 1435-1445.
[44] Patterson MC, Vecchio D, Jacklin E, et al. Long-term miglustat therapy in children with Niemann-Pick disease type C[J]. J Child Neurol, 2010, 25(3): 300-305.
[45] Wraith JE, Vecchio D, Jacklin E, et al. Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial[J]. Mol Genet Metab, 2010, 99(4): 351-357.
[46] Patterson MC, Vecchio D, Prady H, et al. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study[J]. Lancet Neurol, 2007, 6(9): 765-772.
[47] Pineda M, Wraith JE, Mengel E, et al. Miglustat in patients with Niemann-Pick disease Type C (NP-C): a multicenter observational retrospective cohort study[J]. Mol Genet Metab, 2009, 98(3): 243-249.
[48] Belmatoug N, Burlina A, Giraldo P, et al. Gastrointestinal disturbances and their management in miglustat treated patients[J]. Inherit Metab Dis, 2011, 34(5): 991-1001.
[49] Champion H, Ramaswami U, Imrie J, et al. Dietary modifications in patients receiving miglustat[J]. Inherit Metab Dis, 2010, 33 Suppl 3: S379-S383.
[50] Marín T, Contreras P, Castro JF, et al. Vitamin E dietary supplementation improves neurological symptoms and decreases c-Abl/p73 activation in Niemann-Pick C mice[J]. Nutrients, 2014, 6(8): 3000-3017.
[51] Walterfang M, Chien YH, Imrie J, et al. Dysphagia as a risk factor for mortality in Niemann-Pick disease type C: systematic literature review and evidence from studies with miglustat[J]. Orphanet J Rare Dis, 2012, 7: 76.
[52] Rosenbaum AI, Cosner CC, Mariani CJ, et al. Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics[J]. Med Chem, 2010, 53(14): 5281-5289.
[53] Abi-Mosleh L, Infante RE, Radhakrishnan A, et al. Cyclodextrin overcomes deficient lysosome-to-endoplasmic reticulum transport of cholesterol in Niemann-Pick type C cells[J]. Proc Natl Acad Sci U S A, 2009, 106(46): 19316-19321.
[54] Liu B, Ramirez CM, Miller AM, et al. Cyclodextrin overcomes the transport defect in nearly every organ of NPC1 mice leading to excretion of sequestered cholesterol as bile acid[J]. Lipid Res, 2010, 51(5): 933-944.
[55] 潘静, 耿哲, 江华, 等. 异基因造血干细胞移植治疗儿童尼曼匹克病1例报告[J]. 中国当代儿科杂志, 2013, 15(9): 782-784.
[56] Bonney DK, O'Meara A, Shabani A, et al. Successful allogeneic bone marrow transplant for Niemann-Pick disease type C2 is likely to be associated with a severe 'graft versus substrate' effect[J]. Inherit Metab Dis, 2010, 33 Suppl 3: S171-S173.